Default company panoramic image
93e4bab7 aedb 48c1 8c27 4545ddcffefd

Therex LLC

Therex is developing a nanotechnology-based bone regeneration device to repair large and critical defects in the craniofacial region.

  • Stage Product In Development
  • Industry Medical Devices and Equipment
  • Location Buffalo, NY, USA
  • Currency USD
  • Founded July 2002
  • Employees 2

Company Summary

Therex focuses on the discovery and development of new modalities for the improved treatment of bone defects, infectious diseases, cancer and inflammation. All are disorders of urgent and unmet medical needs but especially those conditions where Therex interests currently rest such as drug resistant bacterial infections and craniofacial bone defects. Therex's customer are large pharmaceutical companies with a presence in these therapeutic areas.


  • Default avatar
    Joseph A. Dunn
    Managing Partner

    Joseph A. Dunn earned his BS (chemistry) and PhD (pharmacology) from the State University of New York at Buffalo School of Pharmacy in 1975 and 1981 respectively. In his professional career, Dr. Dunn has held several positions including Fellow of Harvard University, Senior Scientist at the Sterling Winthrop Company and Deputy Under Secretary for Research at USDA. In addition to his current position at Therex, Dr. Dunn is also the Associate

  • Default avatar
    Robert J. Genco

    Robert J. Genco, DDS., PhD, is the director of the Buffalo Periodontal Disease Research Center and vice provost of the University at Buffalo (UB) Office of Science, Technology Transfer and Economic Outreach. His research interests include studying the causes, risk factors and systemic effects of periodontal disease, as well as its management. A cum laude graduate of the State University of New York at Buffalo School of Dentistry, Dr. Genco recei

  • Default avatar
    Richard T. Evans

    Richard T. Evans, PhD is Professor Emeritus, School of Dental Medicine, SUNY at Buffalo. Dr. Evans obtained his PhD degree in microbiology from the University of Missouri, Columbia. His primary areas of research is the evaluation of novel chemotherapeutic agents against periodontal diseases for use in humans, and investigations into the feasibility of using moldable nanoCalcium sulfate as a structural device for bone regeneration in situ.

  • Default avatar
    Robert A. Coburn

    Robert A. Coburn, PhD is Professor Emeritus, School of Pharmacy, Department of Medicinal Chemistry, SUNY Buffalo. Dr. Coburn, who obtained his PhD degree in chemistry from Harvard University, has as his primary areas of research the design and synthesis of novel, topically active chemotherapeutic agents, and particularly agents for use in the oral cavity as treatments for gingivitis and periodontal diseases.

  • Default avatar
    Kenneth A. Walters

    Kenneth A Walters obtained his PhD degree in pharmaceutics from the University of Strathclyde in 1978. Dr Walters has held several positions in both industry and academia. His research interests are in the field of membrane permeation, enhancement and retardation and surfactant effects on biological systems. In addition to his responsibilities at Therex, Dr. Walters is also a Director at An-eX Analytical Services Ltd (Cardiff, CF1 3XF, UK) and a


  • Default avatar
    Paul A. Mitchell; Lippes, Mathias, Wexler and Friedman, Buffalo, NY
    Default avatar
    Mark Kane, CPA; The Kane Firm, Amherst, NY